These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36059942)

  • 1. Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review.
    Zhang X; Han H; Zhao J; Liu X; Zhang J; Sun R; Li S; Liu B; Zhu H; Jiao S; Li X; Tang H
    Front Pharmacol; 2022; 13():964606. PubMed ID: 36059942
    [No Abstract]   [Full Text] [Related]  

  • 2. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
    Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
    Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.
    Chen X; Zha W; Su M; Meng N; Cao S; Niu B; Qi X
    Front Pharmacol; 2023; 14():1053805. PubMed ID: 36817153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced lung adenocarcinoma patient with
    Jia K; Yang S; Chen B; Yu J; Wu Y; Li W; Zhou F; Wu F; Feng G; Ren S
    Ann Transl Med; 2022 Mar; 10(6):386. PubMed ID: 35433998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
    Zhang SS; Ou SI
    Lung Cancer (Auckl); 2022; 13():67-73. PubMed ID: 36317157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 8. Osimertinib in uncommon
    Wang Y; Dorwal P; Rajadurai S; Arulananda S
    Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Lung Adenocarcinoma Patient With a Rare
    Wei Y; Cui Y; Guo Y; Li L; Zeng L
    Front Oncol; 2021; 11():700345. PubMed ID: 34178699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in
    Pan X; Shi M
    Heliyon; 2024 Mar; 10(5):e27106. PubMed ID: 38439894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer.
    Hu S; Ming H; He Q; Ding M; Ding H; Li C
    Front Oncol; 2024; 14():1314301. PubMed ID: 38651148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review.
    Chen T; Chen J; Liu DS; Shu YL; Fu MY; Gou HJ; Lei KJ; Jia YM
    Front Oncol; 2023; 13():1233198. PubMed ID: 37920163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
    BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI.
    Ding J; Ding X; Zeng J; Liu X
    Front Pharmacol; 2024; 15():1357913. PubMed ID: 38440180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.